J.P. Morgan Asset Management (JPMAM) has launched JP Morgan Funds Genetic Therapies, an actively managed fund, in partnership with UBS Global Wealth Management.
The fund will combine "machine learning and active equity insights" and leverages UBS research from its longer term investments framework. Genetic therapies are at an "inflection point", currently moving from "clinic to commercial reality", JPMAM said. The Genetic Therapies fund aims to provide investors with the chance to "gain diversified exposure" to this "new and exciting" theme, while helping to hedge the risk of "disruption" to healthcare portfolios. Why healthcare sector is ripe for disruption The fund will be co-managed by Yazann Romahi, Berkan Sesen and Ajiaz Hussein, w...
To continue reading this article...
Join Investment Week for free
Signup and gain exclusive members-only insights - all free of charge!
- Unlimited access to real-time news, analysis and opinion from the investment industry, including the Sustainable Hub covering fund news from the ESG space
- Get ahead of regulatory and technological changes affecting fund management
- Important and breaking news stories selected by the editors delivered straight to your inbox each day
- Weekly members-only newsletter with exclusive opinion pieces from leading industry experts
- Be the first to hear about our extensive events schedule and awards programmes
